SCHEMBL14477247

SCHEMBL14477247

CCOC(=O)C(F)(F)c1ccc(C(O)C(F)(F)F)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.35
▸ GAA P10253 2/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HTT P42858 2/20 0.34
▸ KCNQ3 O43525 1/20 0.33
▸ KCNQ2 O43526 1/20 0.33
▸ KCNQ4 P56696 1/20 0.33
▸ KCNQ5 Q9NR82 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ PDE1B Q01064 1/20 0.33
▸ MAPT P10636 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ OGA O60502 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MLYCD O95822 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ GABRA1 P14867 2/20 0.32
▸ GABRB2 P47870 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14466844 0.88 POLB (0.38) POLBGAAMAPK1SMN1; SMN2HTT
SCHEMBL17583206 0.88 POLB (0.37) POLBGAAMAPK1SMN1; SMN2HTT
SCHEMBL17420743 0.86 HTT (0.40) POLBGAAMAPK1SMN1; SMN2HTT
SCHEMBL3891001 0.80 KDM4E (0.48) POLBGAAMAPK1SMN1; SMN2HTT
SCHEMBL17113764 0.79 POLB (0.49) POLBGAAMAPK1SMN1; SMN2HTT
SCHEMBL161047 0.79 MAPT (0.42) POLBGAAMAPK1SMN1; SMN2HTT
SCHEMBL20406093 0.79 KMT2A (0.41) POLBGAAMAPK1SMN1; SMN2HTT
SCHEMBL17118220 0.78 GABRA1 (0.37) POLBGAAMAPK1SMN1; SMN2HTT
SCHEMBL14332032 0.78 HTT (0.46) POLBGAAMAPK1SMN1; SMN2HTT
SCHEMBL14466833 0.78 KCNQ3 (0.42) POLBGAAMAPK1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9556143-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-01-31 — — US disclosed
US-9221791-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2015-12-29 — — US disclosed
US-20150099750-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-04-09 — — US disclosed
US-8901121-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2014-12-02 — — US disclosed
US-20140350003-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2014-11-27 — — US disclosed
US-8809378-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2014-08-19 — — US disclosed
US-20130005719-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2013-01-03 — — US disclosed
US-20130005729-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2013-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005729-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO POLB 1777/4885GAA 6/4885MAPK1 3450/4885
US-20150099750-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO POLB 1777/4885GAA 6/4885MAPK1 3450/4885
US-20140350003-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO POLB 1777/4885GAA 6/4885MAPK1 3450/4885
US-20130005719-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO POLB 1777/4885GAA 6/4885MAPK1 3450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback